



(51) International Patent Classification:

A61K 31/519 (2006.01) *A61P 25/00* (2006.01)
A61K 31/53 (2006.01)

(21) International Application Number:

PCT/EP2012/054258

(22) International Filing Date:

12 March 2012 (12.03.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/453,808 17 March 2011 (17.03.2011) US
11002210.0 17 March 2011 (17.03.2011) EP

(71) Applicant (for all designated States except US): **ALGIAX PHARMACEUTICALS GMBH** [—/DE]; Max-Planck-Straße 15a, 40699 Erkrath (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KOOPMANS, Guido** [NL/NL]; Romeinseweg 25, NL-6135 JA Sittard (NL). **HASSE, Birgit** [DE/DE]; Katernberger Straße 171, 42115 Wuppertal (DE).

(74) Agent: **ROTH, Andy Stefan**; DR. ROTH Patentanwalt-skanzlei, Columbusstraße 22, 40549 Düsseldorf (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL USE OF IMIDAZOTRIAZINONES

(57) Abstract: Provided herein are compounds for use in the treatment of central nervous system (CNS)-trauma related disorders like spinal cord injuries. Pharmaceutical compositions, single unit dosage forms, and kit suitable for use for the treatment of (CNS)-trauma related disorders are also disclosed.



WO 2012/123406 A1

5

10

NOVEL USE OF IMIDAZOTRIAZINONES

FIELD OF THE DISCLOSURE

15 The technology provided herein relates to the novel use of imidazotriazinones derivatives in the treatment of central nervous system (CNS)-trauma related disorders.

BACKGROUND

20 Central nervous system (CNS) trauma, caused by injuries such as spinal and head injuries, cause, when not-fatal, devastating physical and psychological effects to the human body. Many of these injuries are caused by common events such as automobile accidents, serious falls, diving accidents, crushing industrial injuries and gunshot or stab wounds.

25 Spinal cord injury (SCI) and traumatic brain injury (TBI) cause tissue damage through both direct and indirect, or secondary, means. Direct tissue damage is typically caused by direct mechanical injury to the tissue. Secondary tissue damage is believed to be caused by the activation of endogenous, autodestructive, neurochemical substances. Other types of acute CNS injuries, such as stroke or hypoxia, also exhibit secondary tissue damage that shares many of the secondary injury factors associated with neurotrauma.

30 Traumatic brain injury (TBI) is an example of mechanical damage. The pathophysiology of TBI can be separated into primary injury and secondary injury. Primary injury occurs at the time of impact, while secondary injury occurs after the impact secondary to the body's response to primary injury. Each of primary and secondary injuries can be subdivided into focal and diffuse types. Focal injury tends to be caused by contact forces, whereas diffuse injury is likely to be caused by noncontact, acceleration-deceleration, or rotational forces.

5 Diffuse axonal injury (DAI) is caused by forces associated with acceleration- deceleration and rotational injuries. DAI is an axonal shearing injury of the axons that is most often observed in the midline structures, including the parasagittal white matter of the cerebral cortex, the corpus callosum, and the pontine-mesencephalic junction adjacent to the superior cerebral peduncles. Posttraumatic syndrome may develop following traumatic injury. The syndromes
10 include hydrocephalus, altered level of consciousness, headache, migraine, nausea, emesis, memory loss, dizziness, diplopia, blurred vision, emotional lability, sleep disturbances, irritability, inability to concentrate, nervousness, behavioral impairment, cognitive deficit, and epilepsy. Seizures are commonly observed with contusions, depressed skull fracture and severe head injury. Intracranial infections are another potential complication of TBI. When basilar skull
15 fractures or cerebrospinal fluid fistulae are present, the risk of infection is increased. Other causes of CNS injury/damage include neurochemical and cellular changes, hypotension, hypoxia, ischemia, electrolyte imbalances, increased ICP with decreased cerebral perfusion pressure (CPP) and a risk of herniation. Acute loss of circulation to an area of the brain results in ischemia and a corresponding loss of neurologic function. Classified as either hemorrhagic or ischemic,
20 strokes typically manifest with the sudden onset of focal neurologic deficits, such as weakness, sensory deficit, or difficulties with language. Ischemic strokes have a heterogeneous group of causes, including thrombosis, embolism, and hypoperfusion, whereas hemorrhagic strokes can be either intraparenchymal or subarachnoid. As blood flow decreases, neurons cease functioning, and irreversible neuronal ischemia and injury begin at blood flow rates of less than
25 18 mL/100 mg/min.

The processes involved in stroke injury at the cellular level are referred to as the ischemic cascade. Within seconds to minutes of the loss of glucose and oxygen delivery to neurons, the cellular ischemic cascade begins. The process begins with cessation of the electrophysiologic function of the cells. The resultant neuronal and glial injury produces edema
30 in the ensuing hours to days after stroke, causing further injury to the surrounding neuronal tissues.

Spinal cord injury (SCI) is an insult to the spinal cord resulting in a change, either temporary or permanent, in its normal motor, sensory, or autonomic function.

Primary SCI arises from mechanical disruption, transection, extradural pathology, or
35 distraction of neural elements. This injury usually occurs with fracture and/or dislocation of the

5 spine. However, primary SCI may occur in the absence of spinal fracture or dislocation. Penetrating injuries due to bullets or weapons may also cause primary SCI. More commonly, displaced bone fragments cause penetrating spinal cord or segmental spinal nerve injuries. Extradural pathology may also cause primary SCI. Spinal epidural hematomas or abscesses cause acute cord compression and injury. Spinal cord compression from metastatic disease is a
10 common oncologic emergency. Longitudinal distraction with or without flexion and/or extension of the vertebral column may result in primary SCI without spinal fracture or dislocation.

The pathophysiology of secondary SCI involves a multitude of cellular and molecular events which progress over the first few days after injury. The most important cause of secondary SCI is vascular injury to the spinal cord caused by arterial disruption, arterial
15 thrombosis, and hypoperfusion due to shock. SCI can be sustained through ischemia from damage or impingement on the spinal arteries. SCI due to ischemia can occur during surgery where aortic blood flow is temporarily stopped.

Spinal cord injury can also be caused by toxicity. One of the most compelling toxicity in spinal cord injury is the accumulation and subsequent damage exerted by the excitatory amino
20 acid neurotransmitter. Glutamate induced excitotoxicity causes an elevation of intracellular calcium. Raised intracellular calcium can in turn cause activation of calcium dependent proteases or lipases which cause further damage due to breakdown of cytoskeletal components including neurofilaments and dissolution of cell membranes. The excess production of arachidonic acid and eicosanoids such as prostaglandins may be related to lipid peroxidation and
25 oxygen free radicals. The release of vasoactive eicosanoids from damaged neuronal membranes may in turn cause progressive posttraumatic ischemia by inducing vasospasm. Endogenous opioids may also be involved in the secondary injury process either by their effects on the local or systemic circulation or by direct effects on the injured cord.

Neurogenic shock can result from SCI. Neurogenic shock refers to the hemodynamic
30 triad of hypotension, bradycardia, and peripheral vasodilation resulting from autonomic dysfunction and the interruption of sympathetic nervous system control in acute SCI, and is differentiated from spinal and hypovolemic shock. Hypovolemic shock tends to be associated with tachycardia. Spinal shock is defined as the complete loss of all neurologic function, including reflexes and rectal tone, below a specific level that is associated with autonomic
35 dysfunction. An initial increase in blood pressure is noted due to the release of catecholamines,

5 followed by hypotension. Flaccid paralysis, including of the bowel and bladder, is observed, and sometimes sustained priapism develops. These symptoms tend to last several hours to days until the reflex arcs below the level of the injury begin to function again.

Current therapy for SCI aims to improve motor function and sensation in patients with the disorder. At present, there are no agents that are consistently effective in treating the
10 disorder. Corticosteroids are the mainstay of therapy. Glucocorticoids such as methylprednisolone are thought to reduce the secondary effects of acute SCI, and the use of high-dose methylprednisolone in non-penetrating acute SCI has increased over the last decade especially in North America. However, the validities of the results are questionable.

Therefore, new methods and compounds that are able to treat CNS-trauma related
15 disorders are needed.

SUMMARY OF THE DISCLOSURE

In a first aspect, embodiments of this disclosure provide the use of imidazotriazinones in the treatment of central nervous system (CNS)-trauma related disorders.

20 In still another aspect, embodiments of this disclosure provide pharmaceutical compositions, single unit dosage forms, and kits comprising imidazotriazinones suitable for use in the treatment of central nervous system (CNS)-trauma related disorders.

In a further aspect, embodiments of this disclosure relate to methods of treating and preventing CNS-trauma related disorders which comprise administering to a patient in need of
25 such treatment or prevention a therapeutically or prophylactically effective amount of a imidazotriazinone.

In other aspects, this disclosure relates to imidazotriazinones or pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, or prodrugs thereof for use in the treatment of central nervous system (CNS)-trauma related disorders.

30

BRIEF DESCRIPTION OF THE DRAWINGS

5 FIG. 1A shows the results of 7-(4-tert-Butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one on axonal growth of embryonic DRG explants.

 FIG. 1B shows the results of 7-(4-tert-Butylcyclohexyl)-5-ethyl-2-phenylimidazo [5,1-f][1,2,4]triazin-4(3H)-one on Schwann cell expansion of embryonic DRG explants.

 FIG. 2 shows the BBB score after contusion and intrathecal application of a
10 imidazotriazinone.

 FIG. 3 shows the results of the explorative rearing test in vehicle animals and in imidazotriazinone treated animals.

 FIG. 4 shows the BBB score after contusion and oral treatment with imidazotriazinone.

 FIG. 5 shows the individual BBB score at DPO 56 of imidazotriazinone, and vehicle
15 treated animals.

DETAILED DESCRIPTION OF THIS DISCLOSURE


 Disclosed herein are the use of imidazotriazinones, active metabolites and/or derivatives thereof for the treatment of central nervous system (CNS)-trauma related disorders.

20 For example, (CNS)-trauma related disorders include complete spinal cord injury, incomplete spinal cord injury, spinal cord contusion, spinal cord compression, spinal cord trauma, spinal injury, paraplegia, quadriplegia, tetraplegia, central cord syndrome, Brown-Séquard syndrome, anterior cord syndrome, conus medullaris syndrome, cauda equina syndrome, traumatic brain injury, TBI, brain injury, brain damage, head injury, diffuse axonal
25 injury (DAI), head trauma, brain concussion, brain contusion, subdural hematoma, epidural hematoma, subarachnoid hemorrhage, intracerebral hemorrhage, and CNS compression.

 In advantageous embodiments of the present disclosure, the (CNS)-trauma related disorder is a spinal cord injury like complete spinal cord injury, incomplete spinal cord injury, spinal cord contusion, spinal cord compression, spinal cord trauma, spinal injury. In
30 advantageous embodiments the (CNS)-trauma related disorder is spinal cord contusion.

5 In an advantageous embodiment the specific compounds of the disclosure are imidazotriazinone derivatives and metabolites described in U.S. patent nos. 7,115,602 B2 and WO 02/098879 A1, which are both, incorporated herein by reference.

The present disclosure relates to the use of compound with the general formula (I)



10 in which R¹ denotes (C₆-C₁₀)-aryl, which is optionally substituted by identical or different residues selected from the group consisting of halogen, (C₁-C₄)-alkyl, tri fluoromethyl, cyano, nitro und trifluoromethoxy, or denotes (C₁-C₈)-alkyl, which is optionally substituted by 3- to 10-membered carbocyclyl, or denotes 3-to 10-membered carbocyclyl, which is optionally substituted by identical or different (C₁-C₄)-alkyl residues, and

15 R² denotes 4-*tert*-butyl-cyclohex-1-yl,

Another embodiment of the disclosure relates to the use according to the present disclosure of compounds of the general formula (I), in which

R¹ denotes naphthyl, or denotes phenyl, which is optionally substituted by identical or different halogen atoms and


20 R² has the meaning indicated above.

Another embodiment of the disclosure relates to the use of compounds of the general formula (I), in which R¹ has the meaning indicated above, and R² denotes *cis*-4-*tert*-butylcyclohex-1-yl.

25 The compounds according to this disclosure can also be present in the form of their salts, hydrates and/or solvates.

5 In advantageous embodiments, the compound used for the treatment of CNS-trauma related disorders is a 7-(4-tert butyl-cyclohexyl)-imidazotriaziones.

Advantageous embodiments of compounds used for the treatment of (CNS)-trauma related disorders include, but not limited to compounds with the following structure (formula II):



10

In further advantageous embodiments, the compound is 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

15 In further advantageous embodiments, a compound according to the present disclosure is used as the only physically active compound in the treatment of CNS-trauma related disorders without a second active agent.

20 In yet other advantageous embodiments, the disclosure relates to pharmaceutical compositions for preventing and/or treating CNS-trauma related disorders, which comprises a therapeutically effective amount of a compound according to the present disclosure in admixture with a pharmaceutical acceptable carrier or excipient.

In advantageous embodiments, the pharmaceutical composition according to the present disclosure comprises a compound according to the present disclosure and no second active ingredient in the composition. In an advanced embodiment, 7-(4-tert-butylcyclohexyl)-5-

5 ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one is used as the sole active agent for the treatment of CNS-trauma related disorders. In an advanced embodiment, 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one is used for the treatment of CNS-trauma related disorders without an immunomodulatory compound as a second active agent.

10 In advantageous embodiments, the pharmaceutical composition is used for preventing and/or treating CNS-trauma related disorders, whereby the composition comprises a therapeutically effective amount of imidazotriazinone or a physiologically functional derivative thereof in admixture with a pharmaceutical acceptable carrier or excipient. In advantageous
15 embodiments the pharmaceutical composition comprises 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

Compounds according to the disclosure can either be commercially purchased or prepared according to the methods described in the publications, patents or patent publications disclosed herein. Further, optically pure compositions can be asymmetrically synthesized or
20 resolved using known resolving agents or chiral columns as well as other standard synthetic organic chemistry techniques. Compounds used in the disclosure may include compounds that are racemic, stereomerically enriched or stereomerically pure, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof.

As used herein and unless otherwise indicated, the term "pharmaceutically acceptable
25 salt" encompasses non-toxic acid and base addition salts of the compound to which the term refers. Acceptable non-toxic acid addition salts include those derived from organic and inorganic acids or bases known in the art, which include, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulphonic acid, acetic acid, tartaric acid, lactic acid, succinic acid, citric acid, malic acid, maleic acid, sorbic acid, aconitic acid, salicylic acid, phthalic
30 acid, embolic acid, enanthic acid, and the like. Compounds that are acidic in nature are capable of forming salts with various pharmaceutically acceptable bases. The bases that can be used to prepare pharmaceutically acceptable base addition salts of such acidic compounds are those that form non-toxic base addition salts, i.e., salts containing pharmacologically acceptable cations such as, but not limited to, alkali metal or alkaline earth metal salts and the calcium,
35 magnesium, sodium or potassium salts in particular. Suitable organic bases include, but are not

5 limited to, N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), lysine, and procaine.

Examples for physiologically acceptable salts can also be salts of the compounds according to this disclosure with inorganic or organic acids. Preferred salts are those with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or
10 sulphuric acid, or salts with organic carboxylic or sulphonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, ethanesulphonic acid, benzenesulphonic acid, toluenesulphonic acid or naphthalenedisulphonic acid. Preferred pyridinium salts are salts in combination with halogen.

As used herein, and unless otherwise specified, the term "solvate" means a compound
15 of the present disclosure or a salt thereof that further includes a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. Where the solvent is water, the solvate is a hydrate.

As used herein and unless otherwise indicated, the term "prodrug" means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (*in vitro or in vivo*) to provide the compound. Examples of prodrugs include, but are not limited to,
20 derivatives of compounds according to the present disclosure that comprise biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. Other examples of prodrugs include derivatives of immunomodulatory compounds of the
25 disclosure that comprise -NO, -NO₂, -ONO, or -ONO₂ moieties. Prodrugs can typically be prepared using well-known methods, such as those described in Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., 5th ed. 1995), and Design of Prodrugs (H. Bundgaard ed., Elsevier, New York 1985). As used herein and unless otherwise indicated, the terms "biohydrolyzable amide," "biohydrolyzable ester," "biohydrolyzable
30 carbamate," "biohydrolyzable carbonate," "biohydrolyzable ureide," "biohydrolyzable phosphate" mean an amide, ester, carbamate, carbonate, ureide, or phosphate, respectively, of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties *in vivo*, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted *in vivo* to the biologically
35 active compound. Examples of biohydrolyzable esters include, but are not limited to, lower alkyl

5 esters, lower acyloxyalkyl esters (such as acetoxyethyl, acetoxyethyl, aminocarbonyloxymethyl, pivaloyloxymethyl, and pivaloyloxyethyl esters), lactonyl esters (such as phthalidyl and thiophthalidyl esters), lower alkoxyacyloxyalkyl esters (such as methoxycarbonyl-oxymethyl, ethoxycarbonyloxyethyl and isopropoxycarbonyloxyethyl esters), alkoxyalkyl esters, choline esters, and acylamino alkyl esters (such as acetamidomethyl esters).
10 Examples of biohydrolyzable amides include, but are not limited to, lower alkyl amides, [alpha]-amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides. Examples of biohydrolyzable carbamates include, but are not limited to, lower alkylamines, substituted ethylenediamines, amino acids, hydroxyalkylamines, heterocyclic and heteroaromatic amines, and polyether amines.

15 As used herein, and unless otherwise specified, the term "stereoisomer" encompasses all enantiomerically/stereomerically pure and enantiomerically/stereomerically enriched compounds of this disclosure. Furthermore, the term "stereoisomer" includes also tautomers which are isomers of organic compounds that readily interconvert by a chemical reaction (tautomerization).

20 As used herein, and unless otherwise indicated, the term "stereomerically pure" or "enantiomerically pure" means that a compound comprises one stereoisomer and is substantially free of its counter stereoisomer or enantiomer. For example, a compound is stereomerically or enantiomerically pure when the compound contains 80%, 90%, or 95% or more of one stereoisomer and 20%, 10%, or 5% or less of the counter stereoisomer, in certain
25 cases, a compound of the disclosure is considered optically active or stereomerically/enantiomerically pure (i.e., substantially the R-form or substantially the S-form) with respect to a chiral center when the compound is about 80% ee (enantiomeric excess) or greater, preferably, equal to or greater than 90% ee with respect to a particular chiral center, and more preferably 95% ee with respect to a particular chiral center.

30 As used herein, and unless otherwise indicated, the term "stereomerically enriched" or "enantiomerically enriched" encompasses racemic mixtures as well as other mixtures of stereoisomers of compounds of this disclosure (e.g., R/S = 30/70, 35/65, 40/60, 45/55, 55/45, 60/40, 65/35 and 70/30). Various inhibitor compounds of the present disclosure contain one or more chiral centers, and can exist as racemic mixtures of enantiomers or mixtures of
35 diastereomers. This disclosure encompasses the use of stereomerically pure forms of such

5 compounds, as well as the use of mixtures of those forms. For example, mixtures comprising equal or unequal amounts of the enantiomers of a particular inhibitor compound of the disclosure may be used in methods and compositions of the disclosure. These isomers may be asymmetrically synthesized or resolved using standard techniques such as chiral columns or chiral resolving agents. See, e.g., Jacques, J., et al, Enantiomers, Racemates and Resolutions
10 (Wiley-Interscience, New York, 1981); Wilen, S. H., et al, Tetrahedron 33:2725 (1977); Eliel, E. L., Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S. H., Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972).

15 It should be noted that if there is a discrepancy between a depicted structure and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it.

20 The term "physiologically functional derivative" as used herein refers to compounds which are not pharmaceutically active themselves but which are transformed into their pharmaceutical active form in vivo, i. e. in the subject to which the compound is administered. Examples of physiologically functional derivatives are prodrugs such as those described below in the present application.

25 The term "derivative" as used herein refers to a compound that is derived from a similar compound or a compound that can be imagined to arise from another compound, if one atom is replaced with another atom or group of atoms. The term "derivative" as used herein refers also to a compound that at least theoretically can be formed from the precursor compound (see Oxford Dictionary of Biochemistry and Molecular Biology. Oxford University Press. ISBN 0-19-850673-2.)

30 The disclosure is also directed to the use of compounds of the formula I or II and of their pharmacologically tolerable salts or physiologically functional derivatives for the production of a medicament for the prevention and treatment of CNS-trauma.

Methods and uses according to the present disclosure encompass methods of preventing, treating and/or managing CNS injury/damage and related syndromes and CNS-

5 trauma related disorders and CNS-trauma related conditions including, but are not limited to, primary brain injury, secondary brain injury, traumatic brain injury, focal brain injury, diffuse axonal injury, head injury, concussion, post-concussion syndrome, cerebral contusion and laceration, subdural hematoma, epidermal hematoma, post-traumatic epilepsy, chronic vegetative state, complete SCI, incomplete SCI, acute SCI, subacute SCI, chronic SCI, central cord
10 syndrome, Brown- Sequard syndrome, anterior cord syndrome, conus medullaris syndrome, cauda equina syndrome, neurogenic shock, spinal shock, altered level of consciousness, headache, nausea, emesis, memory loss, dizziness, diplopia, blurred vision, emotional lability, sleep disturbances, irritability, inability to concentrate, nervousness, behavioral impairment, cognitive deficit, and seizure.

15 The symptoms, conditions and/or disorders associated with CNS injury/damage and CNS-trauma include, but are not limited to, motor weakness (especially paraparesis or quadriplegia with or without respiratory distress); loss of sensation or bowel or bladder control; sexual dysfunction; symptoms of neurogenic shock such as lightheadedness, diaphoresis, bradycardia, hypothermia, hypotension without compensatory tachycardia;
20 respiratory insufficiency; quadriplegia with upper and lower extremity areflexia; anesthesia below the affected level; loss of rectal and bladder sphincter tone; urinary and bowel retention leading to abdominal distention, ileus, and delayed gastric emptying; ipsilateral ptosis, miosis, anhydrosis; paralysis with loss of temperature sensation; relative sparing of touch, vibration, and proprioception; dissociated sensory loss; arm weakness, patch sensory loss below the level
25 of the lesion; loss of vibration and position sense below the level of the lesion, hyperreflexia, and an extensor toe sign; ipsilateral segmental anesthesia; and polyradiculopathy, radicular sensory changes, asymmetric lower motor neuron- type leg weakness, and sphincter disturbances.

The suitability of a particular route of administration of a compound according to the
30 present disclosure employed for a particular active agent will depend on the active agent itself (e.g., whether it can be administered orally without decomposing prior to entering the blood stream) and the disease being treated. An advantageous embodiment of the route of administration for a compound according to the present disclosure is orally. Further routes of administration are known to those of ordinary skill in the art.

5 The dosage of therapeutically effective amount of at least one compound varies from and also depends upon the age and condition of each individual patient to be treated. In an embodiment of the present disclosure, the recommended daily dose range of a compound according to the present disclosure for the conditions and disorders described herein lies within the range of from about, a daily dose of about 1 mg-10g/body, preferable 5 mg-5g/body and
10 more preferable 10 mg-2g/body of the active ingredient is generally given for preventing and /or treating this disease, and an average single dose of about 0.5-1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg, 1 g, 2 g and 3 g is generally administered. Daily dose for administration in humans for preventing this disease (CNS trauma related disorders) could be in the range of about 0.1-50 mg/kg.

15 While the term for administering of at least one compound to prevent this disease (CNS trauma related disorders) varies depending on species, and the nature and severity of the condition to be prevented, the compound may usually be administered to humans for a short term or a long term, i.e. for 1 week to 1 year.

 Pharmaceutical compositions can be used in the preparation of individual, single unit
20 dosage forms. The compounds of the present disclosure can be used in the form of pharmaceuticals compositions, for example, in solid, semisolid or liquid form, which contains one or more of the compounds according to the present disclosure as active ingredient associated with pharmaceutically acceptable carriers or excipient suitable for oral, parenteral such as intravenous, intramuscular, intrathecal, subcutaneous, enteral, intrarectal or intranasal
25 administration. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions (saline for example), emulsion, suspensions (olive oil, for example), ointment and any other form suitable for use. The carriers which can be used are water, glucose, lactose gum acacia, gelatine, manitol, starch paste, magnesium trisilicate, corn starch, keratin, colloidal silica, potato
30 starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid or liquid form, and in addition auxiliary, stabilizing, thickening and colouring agents and perfumes may be used. The active object compound is included in the pharmaceutical composition in an effective amount sufficient to prevent and/or treat the disease.

 Single unit dosage forms of the disclosure are suitable for oral, mucosal (e.g., nasal,
35 sublingual, vaginal, buccal, or rectal), parenteral (e.g., subcutaneous, intravenous, bolus

5 injection, intramuscular, or intraarterial), topical (e.g., eye drops or other ophthalmic preparations), transdermal or transcutaneous administration to a patient. Examples of dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; powders; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in- water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; eye drops or other ophthalmic preparations suitable for topical administration; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.

15 The composition, shape, and type of dosage forms of the disclosure will typically vary depending on their use. For example, a dosage form used in the acute treatment of a disease may contain larger amounts of one or more of the active agents it comprises than a dosage form used in the chronic treatment of the same disease. Similarly, a parenteral dosage form may contain smaller amounts of one or more of the active agents it comprises than an oral dosage form used to treat the same disease. These and other ways in which specific dosage forms encompassed by this disclosure will vary from one another will be readily apparent to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).

25 Typical pharmaceutical compositions and dosage forms comprise one or more excipients. Suitable excipients are well known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients are provided herein. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a patient. For example, oral dosage forms such as tablets may contain excipients not suited for use in parenteral dosage forms. The suitability of a particular excipient may also depend on the specific active agents in the dosage form. For example, the decomposition of some active agents may be accelerated by some excipients such as lactose, or when exposed to water. Active agents that comprise primary or secondary amines are particularly susceptible to such accelerated decomposition. Consequently, this disclosure encompasses pharmaceutical compositions and dosage forms that contain little, if any, lactose

5 or other mono- or di-saccharides. As used herein, the term "lactose-free" means that the amount of lactose present, if any, is insufficient to substantially increase the degradation rate of an active ingredient.

Lactose-free compositions of the disclosure can comprise excipients that are well known in the art and are listed, for example, in the U.S. Pharmacopeia (USP) 25-NF20 (2002). In general,
10 lactose-free compositions comprise active ingredients, a binder/filler, and a lubricant in pharmaceutically compatible and pharmaceutically acceptable amounts. Preferred lactose-free dosage forms comprise active ingredients, microcrystalline cellulose, pre-gelatinized starch, and magnesium stearate.

This disclosure further encompasses anhydrous pharmaceutical compositions and
15 dosage forms comprising active ingredients, since water can facilitate the degradation of some compounds. For example, the addition of water (e.g., 5%) is widely accepted in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. See, e.g., Jens T. Carstensen, Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-
20 80. In effect, water and heat accelerate the decomposition of some compounds. Thus, the effect of water on a formulation can be of great significance since moisture and/or humidity are commonly encountered during manufacture, handling, packaging, storage, shipment, and use of formulations.

Anhydrous pharmaceutical compositions and dosage forms of the disclosure can be
25 prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprise a primary or secondary amine are preferably anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected. An anhydrous pharmaceutical composition should be
30 prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are preferably packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g. vials), blister packs, and strip packs.

5 The disclosure further encompasses pharmaceutical compositions and dosage forms that comprise one or more compounds that reduce the rate by which an active ingredient will decompose. Such compounds, which are referred to herein as "stabilizers," include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers.

10 Like the amounts and types of excipients, the amounts and specific types of active agents in a dosage form may differ depending on factors such as, but not limited to, the route by which it is to be administered to patients. However, typical dosage forms of the disclosure comprise a compound according to the present disclosure or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof in an amount of from about 0.10 to about 150 mg. Typical dosage forms comprise a compound according to the present disclosure
15 or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof in an amount of about 0.1, 1, 2, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 50, 100, 150 or 200 mg. In a particular embodiment, a preferred dosage form comprises a compound according to the present description in an amount of about 1, 2, 5, 10, 25 or 50mg. In a specific embodiment, a preferred dosage form comprises a compound according to the present description in an
20 amount of about 5, 10, 25 or 50mg.

 Oral Dosage Forms of pharmaceutical compositions of the disclosure that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups). Such dosage forms contain predetermined amounts of active ingredients, and may be prepared by
25 methods of pharmacy well known to those skilled in the art. See generally, Remington 's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).

 Typical oral dosage forms of the disclosure are prepared by combining the active ingredients in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques. Excipients can take a wide variety of forms depending
30 on the form of preparation desired for administration. For example, excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents. Examples of excipients suitable for use in solid oral dosage forms (e.g., powders, tablets, capsules, and caplets) include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants,
35 binders, and disintegrating agents.

5 Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid excipients are employed. If desired, tablets can be coated by standard aqueous or nonaqueous techniques. Such dosage forms can be prepared by any of the methods of pharmacy. In general, pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with
10 liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary.

 For example, a tablet can be prepared by compression or molding. Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with an excipient. Molded tablets can be
15 made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

 Examples of excipients that can be used in oral dosage forms of the disclosure include, but are not limited to, binders, fillers, disintegrants, and lubricants. Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch,
20 potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, (e.g., Nos. 2208, 2906, 2910), microcrystalline cellulose, and
25 mixtures thereof.

 Suitable forms of microcrystalline cellulose include, but are not limited to, the materials sold as AVICEL-PH-101, AVICEL-PH-103 AVICEL RC-581, AVICEL-PH-105 (available from FMC Corporation, American Viscose Division, Avicel Sales, Marcus Hook, PA), and mixtures thereof. A specific binder is a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose sold
30 as AVICEL RC-581. Suitable anhydrous or low moisture excipients or additives include AVICEL-PH- 103(TM) and Starch 1500 LM. Examples of fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. The

5 binder or filler in pharmaceutical compositions of the disclosure is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form.

Disintegrants are used in the compositions of the disclosure to provide tablets that disintegrate when exposed to an aqueous environment. Tablets that contain too much disintegrant may disintegrate in storage, while those that contain too little may not disintegrate
10 at a desired rate or under the desired conditions. Thus, a sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredients should be used to form solid oral dosage forms of the disclosure. The amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in the art. Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight
15 percent of disintegrant, preferably from about 1 to about 5 weight percent of disintegrant.

Disintegrants that can be used in pharmaceutical compositions and dosage forms of the disclosure include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrillin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches,
20 clays, other algin, other celluloses, gums, and mixtures thereof.

Lubricants that can be used in pharmaceutical compositions and dosage forms of the disclosure include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil,
25 sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof. Additional lubricants include, for example, a syloid silica gel (AEROSIL200, manufactured by W.R. Grace Co. of Baltimore, MD), a coagulated aerosol of synthetic silica (marketed by Degussa Co. of Piano, TX), CAB-O-SIL (a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA), and mixtures thereof. If used at all, lubricants are
30 typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.

A preferred solid oral dosage form of the disclosure comprises a compound of the disclosure, anhydrous lactose, microcrystalline cellulose, polyvinylpyrrolidone, stearic acid, colloidal anhydrous silica, and gelatin.

5 Active ingredients of the disclosure can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, and 5,733,566, each of which is incorporated herein by reference. Such dosage forms
10 can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein can be
15 readily selected for use with the active ingredients of the disclosure. The disclosure thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled-release.

All controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts. Ideally, the use of an optimally
20 designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance. In addition, controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as
25 blood levels of the drug, and can thus affect the occurrence of side (e.g., adverse) effects.

Most controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time. In order to maintain this constant level of drug in the
30 body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body. Controlled- release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, temperature, enzymes, water, or other physiological conditions or compounds.

Parenteral dosage forms can be administered to patients by various routes including,
35 but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and

5 intraarterial. Because their administration typically bypasses patients' natural defenses against
contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior
to administration to a patient. Examples of parenteral dosage forms include, but are not limited
to, solutions ready for injection, dry products ready to be dissolved or suspended in a
pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and
10 emulsions. Suitable vehicles that can be used to provide parenteral dosage forms of the
disclosure are well known to those skilled in the art. Examples include, but are not limited to:
Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection,
Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated
Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene
15 glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil,
cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

Compounds that increase the solubility of one or more of the active ingredients
disclosed herein can also be incorporated into the parenteral dosage forms of the disclosure. For
example, cyclodextrin and its derivatives can be used to increase the solubility of a compound of
20 the disclosure and its derivatives. See, e.g., U.S. Patent No. 5,134,127, which is incorporated
herein by reference.

Topical and mucosal dosage forms of the disclosure include, but are not limited to,
sprays, aerosols, solutions, emulsions, suspensions, eye drops or other ophthalmic preparations,
or other forms known to one of skill in the art. See, e.g., Remington 's Pharmaceutical Sciences,
25 16th and 18th eds., Mack Publishing, Easton PA (1980 & 1990); and Introduction to
Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985). Dosage forms
suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes or
as oral gels.

Suitable excipients {e.g., carriers and diluents} and other materials that can be used to
30 provide topical and mucosal dosage forms encompassed by this disclosure are well known to
those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given
pharmaceutical composition or dosage form will be applied. With that fact in mind, typical
excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene
glycol, butane-1,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures
35 thereof to form solutions, emulsions or gels, which are non-toxic and pharmaceutically

5 acceptable. Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well known in the art. See, e.g., Remington 's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton PA (1980 & 1990).

10 The pH of a pharmaceutical composition or dosage form may also be adjusted to improve delivery of one or more active ingredients. Similarly, the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery. Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery. In this regard, stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or 15 surfactant, and as a delivery-enhancing or penetration-enhancing agent. Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.

Typically, active ingredients of the disclosure are preferably not administered to a patient at the same time or by the same route of administration. This disclosure therefore 20 encompasses kits which, when used by the medical practitioner, can simplify the administration of appropriate amounts of active ingredients to a patient.

A typical kit of the disclosure comprises a dosage form of a compound of the disclosure, in an advantageous embodiment of the compound of the formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, prodrug, or clathrate thereof. Kits encompassed 25 by this disclosure can further comprise additional active agents. Examples of the additional active agents include, but are not limited to, those disclosed herein (see, e.g., section 4.2). Kits of the disclosure can further comprise devices that are used to administer the active ingredients. Examples of such devices include, but are not limited to, syringes, drip bags, patches, and inhalers. In an advantageous embodiment, a kit of the disclosure contains imidazotriazinones 30 derivates like the compound of the formula (I) and no additional immunomodulatory compound.

Kits of the disclosure can further comprise cells or blood for transplantation as well as pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients. For example, if an active ingredient is provided in a solid form that must be

5 reconstituted for parenteral administration, the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration. Examples of pharmaceutically acceptable vehicles include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and
10 Sodium Chloride Injection, and Lactated Ringer's Injection; water- miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

An advantageous example for a compound according to the present disclosure for the
15 use in the treatment of CNS-trauma related disorders is 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one.



In further advantageous embodiments, the compounds according to the present disclosure, preferably the imidazotriazinones derivatives, more preferably the compounds with the formula (I) and/or formula (II) like 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-
20 f][1,2,4]triazin-4(3H)-one are used in the treatment of (CNS)-trauma related disorders in combination with leflunomide, active metabolites of leflunomide and/or malononitrilamides.

In an advantageous embodiment the active metabolite of leflunomide is a malononitrilamide and/or a derivative thereof. Specific compounds which can be combined with the compounds according to the present disclosure are such derivatives and metabolites of
25 leflunomide described in U.S: patent nos. 5,532,259, in the international patent application WO 91/717748 and in Kuo et al., (Kuo et al., 1996), each of which is incorporated herein by reference.


Specific examples of compounds which can be combined with the compounds according to the present disclosure for the treatment of (CNS)-trauma related disorders include, but not
30 limited to compounds with the following structures (formula III to VIII):

III) Leflunomide


IV) teriflunomide




V) HR325




VI) FK778 / A



VII) FK778 / B



VIII) MNA279



5 In further advantageous embodiments, the compound which can be combined with the compounds according to the present disclosure is N-(4-trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide, N-(4-trifluoromethyl)-phenyl-2-cyano-3-hydroxy-crotonic acidamide, 1(3-methyl-4-trifluoro methylphenyl-carbamoyl)-2-cyclopropyl-2oxo-propionitrile, is N-(4-trifluoromethyl)-phenyl-2-cyano-3-hydroxy-hept-2-en-6- in-carboxylic acidamide and 2-cyano-3-
10 cyclopropyl-3-oxo-(4-cyanophenyl)propionamide or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

In advantageous embodiments, the compound which can be combined with the compounds according to the present disclosure is 1(3-methyl-4-trifluoro methylphenyl-carbamoyl)-2-cyclopropyl-2oxo-propionitrile or N-(4-trifluoromethyl)-phenyl-2-cyano-3-hydroxy-
15 crotonic acidamide.

In an advantageous embodiment, the compound with the formula II is combined with a compound selected from the group consisting of a compound with the formula (III), (IV), (V), (VI), (VII) and (VIII).

The combinations of the compounds can be part of the kits and/or comprised of the pharmaceutically compositions according to the present disclosure.
20

The following examples and methods are offered for illustrative purposes only, and are not intended to limit the scope of the present disclosure in any way.

Methods and Examples

25 A series of non-clinical pharmacology and toxicology studies have been performed to support the clinical evaluation of the compounds according to the present disclosure in human subjects. These studies were performed in accordance with internationally recognized guidelines for study design and in compliance with the requirements of Good Laboratory Practice (GLP) unless otherwise noted.

30 Example 1

In vitro experiments with an imidazotriazinone to improve axonal growth and Schwann cell expansion in embryonic DRG explants of rats.

5 Methods

Experimental model

Outgrowth studies with 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one or the vehicle were performed on embryonic neural tissue. DRGs of thoracic, lumbar, and sacral levels were prepared from Wistar rat embryos E18-20 and processed in ice cold 0.6% glucose in PBS. Harvested DRGs were freed from attaching nerve fibres, dissected, and transferred onto poly-D-lysine- and laminin-coated glass coverlips. To avoid cluster formation, a maximum of two DRG explants was transferred onto a single glass coverslip. Following an initial attachment phase, the pre-incubation medium was replaced by fully supplemented growth medium spiked with the test item (7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one groups 2 and 3) or vehicle (DMF, group 1) and incubated at 37°C/10% CO₂ for additional 22 hours *in vitro*. Following 22 hours *in vitro*, the DRG explants were fluorescently labelled and axonal growth and Schwann cell expansion were quantitatively assessed.

The following experimental groups were included into the study:

- Fully supplemented growth medium with 0.1% vehicle.
- Fully supplemented growth medium with 0.1% vehicle and 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one at a final concentration of 0.01 µM.
- Fully supplemented growth medium with 0.1% vehicle and 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one at a final concentration of 0.1 µM.
- Fully supplemented growth medium with 0.1% vehicle and 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one at a final concentration of 1 µM.

Results

30 Axonal outgrowth

Results of the morphometric analysis are displayed in Fig. 1A. Morphometric data are presented as the mean values and standard deviations of the axonal growth area in µm². Application of 0.01 - 1 µM 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one led to a significant increase in the growth area of outgrowing axons, as compared to vehicle-treated cultures. Thereby, elevation of axonal growth areas in 7-(4-tert-butylcyclohexyl)-

5 5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one -treated DRG cultures was highest following application of 0.1 μ M

Schwann cell expansion

Results of the counting of expanding Schwann cells are displayed in Fig. 1B. Data are presented as the mean values and standard deviations of the numbers of Schwann cells outside the DRG explant core. Treatment of embryonic DRG explants with 0.01 - 1 μ M 7-(4-tert-butylcyclohexyl)-
10 5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one led to a significant increase in Schwann cell expansion. Thereby, Schwann cell numbers in 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one -treated cultures were increased nearly fourfold, as compared to vehicle-treated cultures, and were highest following application of 0.1 μ M 7-(4-
15 tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one.

Example 2

Intrathecal treatment with a imidazotriazinone after severe spinal cord contusion injury in the rat.

20

Surgical methods

A) Spinal cord contusion injury and positioning of the intrathecal catheter

Thirteen week-old female Lewis rats (Charles River, Sulzfeld Germany) were housed under a 12:12 h dark/light regime and allowed free access to water and food. After one week of
25 habituation the animals underwent general anesthesia with a mixture of isoflurane and air (induction: 5% isoflurane, maintenance: 2.2% isoflurane). A T8 laminectomy was performed without rupturing the dura and a severe contusive SCI (25 gcm NYU/MASCIS II impactor) {Gruner, 1992 #3} was induced. Thereafter, the surgery continued with the procedure to position the silicon tube intrathecal catheter (7740, Alzet). Firstly, the catheter was filled with
30 either the active or the vehicle solution. Secondly, another laminectomy was performed, again without rupturing the dura, at T11. At this position a small incision was made into the dura and the catheter was inserted at thoracic level 11 and pushed forward under lamina of T10 –T9 to the lesion site at T8. The catheter was then cut at the appropriate length and connected to a filled osmotic minipump (Alzet, model 2002) which was placed subcutaneously. The overlying

5 tissue was sutured, and a subcutaneous (s.c.) injection of 5 ml of Ringers Lactate was given. The different solutions (active or vehicle) were infused at a flow rate of 0.5 µl/h over a time period of 14 days. Bladders were emptied manually 2 times a day until spontaneous voiding returned (usually within 1 week). The lesion severity was verified by the impact velocity and contusion depth of the impactor rod. Animals with an impact velocity error > 5% were excluded from
10 further analysis. Two weeks after the first operation, the pumps and catheters were removed in a second surgery. Altogether we investigated forty-eight animals randomly assigned to four different treatment groups:

Group 1: SCI + vehicle II (DMF)

15 *Group 2: SCI + 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one (100µM) in vehicle II*

B) Functional recovery

20 *The BBB open field locomotor rating scale:*

The BBB locomotor rating scale was used to assess general locomotor performance (Basso et al., 1995). The score was assessed before injury and at 1, 3, 5, 7, 14, 21, 35, 42, 49, 56 and 63 days post operation (dpo) by 2 blinded observers.

C) Explorative rearing test:

25 When placed in a Plexiglas cylinder (18 cm diameter × 35.0 cm height), animals spontaneously rear and contact the walls with their forepaws. Numbers, duration and types of rears were analyzed during the 3-min recorded observation period in the cylinder (Himes et al., 2006; Shumsky et al., 2003). A mirror was placed at an angle behind the cylinder so that the
30 forelimbs could be viewed at all times. The testing session was videotaped, and rearing behaviour was scored blindly at a later date.

Different types of rears of increasing heights were observed:

1) Crouch—Animals lifted both forepaws off the ground up to 10cm;

35 2) Rear—Animals reared and extended the trunk with the hindlimbs flexed reaching a height between 10 and 15 cm;

5 3) Stand—Animals reared and extended the trunk with the hindlimbs extended reaching a height between 15 and 20 cm;

4) Reach—Animals stand on their toes and completely extend trunk and hindlimbs reaching a height over 20 cm.

10 Occasionally an animal progressed through several types of rears before touching down, in which case the time the animal spend in each rearing height was measured by counting the single video frames. Data were expressed as number of attempts (rears), attempt duration and the time each animal spend in the different rearing heights.

15 **Results**

Functional recovery

20 The functional recovery as assessed by the BBB locomotor rating scale followed a pattern of progressive recovery over the first 2-3 weeks after injury. Thereafter the spontaneous functional recovery reached a 'steady state'. Based on the BBB locomotor rating scale, a significant effect of the imidazotriazinone treatment was noted over the entire time-period of the assessment (ANOVA-RM; Treatment $F_{1,11} = 8,7$ $p = 0.013$). Figure 2 shows the functional recovery as assessed by the BBB locomotor rating scale. (* $p < 0.05$)

25 The explorative rearing test was used to assess other aspects of functional recovery after injury. One of the parameters that reflect the degree of functional recovery in this test is the time each animal spend in the different rearing heights. The results of this parameter are presented in Figure 3.

30 These results clearly demonstrate that the rearing attempts of the imidazotriazinone treated animals are longer in time and that the forepaws reached much higher when compared to vehicle control animals. This effect was most obvious in rearing, standing and reaching. Imidazotriazinone treated animals were able to perform standing and even reaching, vehicle control animals in contrast were only able to make a crouch or a rear (see figure 3).

5 Altogether, the data presented in example 2 showed that intrathecal imidazotriazinone treatment significantly improves functional recovery after severe spinal cord contusion in the rat.

Example 3

10 **Oral treatment with a imidazotriazinone after severe spinal cord contusion injury in the rat.**

A) Surgical methods

Thirteen week-old female Lewis rats (Charles River, Sulzfeld Germany) were housed under a 12:12 h dark/light regime and allowed free access to water and food. After one week of
15 habituation the animals underwent general anesthesia with a mixture of isoflurane and air (induction: 5% isoflurane, maintenance: 2.2% isoflurane). A Th10 laminectomy was performed without rupturing the dura and a severe contusive SCI (25 gcm NYU/MASCIS II impactor) (Gruner, 1992) was induced. After suturing muscle and skin, a subcutaneous (s.c.) injection of 5 ml of Ringers Lactate was given. Bladders were emptied manually 2 times a day until
20 spontaneous voiding returned (usually within 1 week). The lesion severity was verified by the impact velocity and contusion depth of the impactor rod. Animals with an impact velocity error > 5% were excluded from further analysis. After injury, individual rats were randomly assigned into a treatment group. The following groups were used:

After injury, individual rats were randomly assigned into a treatment group. The following
25 groups were used:

Group 1: SCI + vehicle

Group 2: SCI + 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one (10mg) in vehicle

30 For the BBB open field locomotor rating scale see example 2.

Results:

Functional recovery

The functional recovery as assessed by the BBB locomotor rating scale followed a pattern of progressive recovery over the first 2-3 weeks after injury. Thereafter the spontaneous

functional recovery reached a 'steady state'. However, the imidazotriazinone treated animals reached a steady state at a BBB score of 9.0. The vehicle treated animals on the contrary reached a BBB score of 7.8. Figure 4 shows the functional recovery as assessed by the BBB locomotor rating scale.

At the end of the experiment the imidazotriazinone treated animals performed significantly better as compared to the vehicle controls (Students T-Test; $p=0.0012$). Figure 5 shows individual BBB scores of the imidazotriazinone and vehicle treated animals at DPO 56.

The results show that a controlled pharmacotherapy by compounds according to the present disclosure like imidazotriazinones can be used for treating CNS-trauma related disorders like acute spinal cord injury.

The embodiments of the disclosure described above are intended to be merely exemplary, and those skilled in the art will recognize, or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific compounds, materials, and procedures. All such equivalents are considered to be within the scope of the disclosure.

Additional References

The following additional publications are incorporated herein by references:

Basso, D. M., et al., 1995. A sensitive and reliable locomotor rating scale for open field testing in rats. *J Neurotrauma*. 12, 1-21.

Buttini, M., et al., 1997. Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram. *Br J Pharmacol*. 122, 1483-9.

Gruner, J. A., 1992. A monitored contusion model of spinal cord injury in the rat. *J Neurotrauma*. 9, 123-6; discussion 126-8.

Himes, B. T., et al., 2006. Recovery of function following grafting of human bone marrow-derived stromal cells into the injured spinal cord. *Neurorehabil Neural Repair*. 20, 278-96.


- 5 Meyer-Franke, A., et al., 1995. Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. *Neuron*. 15, 805-19.
- Nijjar, M. S., Nijjar, S. S., 2000. Domoic acid-induced neurodegeneration resulting in memory loss is mediated by Ca^{2+} overload and inhibition of Ca^{2+} + calmodulin-stimulated adenylate cyclase in rat brain (review). *Int J Mol Med*. 6, 377-89.
- 10 Pearse, D. D., et al., 2004. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. *Nat Med*. 10, 610-6.
- Shumsky, J. S., et al., 2003. Delayed transplantation of fibroblasts genetically modified to secrete BDNF and NT-3 into a spinal cord injury site is associated with limited recovery of function. *Exp Neurol*. 184, 114-30.
- 15 Troadec, J. D., et al., 2002. Activation of the mitogen-activated protein kinase (ERK(1/2)) signaling pathway by cyclic AMP potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. *Mol Pharmacol*. 62, 1043-52.
- Witkamp, R., Monshouwer, M., 2000. Signal transduction in inflammatory processes, current and future therapeutic targets: a mini review. *Vet Q*. 22, 11-6.
- 20 Yoshikawa, M., et al., 1999. Effects of phosphodiesterase inhibitors on cytokine production by microglia. *Mult Scler*. 5, 126-33.

WO 02/098879 A1


US 2003/0229134 A1

CLAIMS

1. An imidazotriazinone for use in treating of a central nervous system trauma related disorder.
2. The use of claim 1, wherein the imidazotriazinone is a compound of the general formula (I)



3. The use of any of claims 1 to 2, wherein the imidazotriazinone is a compound of the formula (II)



or a pharmaceutically acceptable salt, solvate, stereoisomer or derivatives thereof.

4. The use of claim 3, wherein the stereoisomer of the compound is the R or S enantiomer.
5. The use of any of claims 1 to 4, wherein the central nervous system trauma related disorder is complete spinal cord injury, incomplete spinal cord injury, spinal cord contusion, spinal cord compression, spinal cord trauma, spinal injury, paraplegia, quadriplegia, tetraplegia, central cord

syndrome, Brown-Séquard syndrome, anterior cord syndrome, conus medullaris syndrome, cauda equina syndrome, traumatic brain injury, TBI, brain injury, brain damage, head injury, diffuse axonal injury (DAI), head trauma, brain concussion, brain contusion, subdural hematoma, epidural hematoma, subarachnoid hemorrhage, intracerebral hemorrhage, or CNS compression.

6. The use of any of claims 1 to 4, wherein the central nervous system trauma related disorder is a spinal cord injury.

7. The use of any of claims 1 to 4, wherein the central nervous system trauma related disorder is a spinal cord contusion.

8. A pharmaceutical composition for the use in the treatment of central nervous system trauma related disorders comprising a imidazotriazinone in free form or in the form of pharmaceutically acceptable salt or physiologically functional derivative, together with pharmaceutically acceptable diluents or carriers.

9. A pharmaceutical composition for the use in the treatment of central nervous system trauma related disorders comprising a compound as defined in claim 2, 3 and/or claim 4 in free form or in the form of pharmaceutically acceptable salt or physiologically functional derivative, together with pharmaceutically acceptable diluents or carriers.

10. A pharmaceutical composition for preventing and/or treating CNS-trauma related disorders, which comprises a therapeutically effective amount of 7-(4-tert-butylcyclohexyl)-5-ethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one or a derivative thereof in admixture with a pharmaceutical acceptable carrier or excipient.


11. The pharmaceutical composition of any of claims 8 to 10, wherein the central nervous system trauma related disorder is complete spinal cord injury, incomplete spinal cord injury, spinal cord contusion, spinal cord compression, spinal cord trauma, spinal injury, paraplegia, quadriplegia, tetraplegia, central cord syndrome, Brown-Séquard syndrome, anterior cord syndrome, conus medullaris syndrome, cauda equina syndrome, traumatic brain injury, TBI, brain injury, brain damage, head injury, diffuse axonal injury (DAI), head trauma, brain concussion, brain contusion, subdural hematoma, epidural hematoma, subarachnoid hemorrhage, intracerebral hemorrhage, or CNS compression.

12. The pharmaceutical composition of any of claims 8 to 10, wherein the central nervous system trauma related disorder is a spinal cord injury.

13. The pharmaceutical composition of any of claims 8 to 10, wherein the central nervous system trauma related disorder is a spinal cord contusion.
14. The pharmaceutical composition of any of claims 8 to 13, wherein the composition comprises further a malononitrilamide.
15. The pharmaceutical composition of claim 14, wherein the malononitrilamide is selected from the group consisting of N-(4-trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide, N-(4-trifluoromethyl)-phenyl-2-cyano-3-hydroxy-crotonic acidamide, 1(3-methyl-4-trifluoro methylphenyl-carbamoyl)-2-cyclopropyl-2-oxo-propionitrile, is N-(4-trifluoromethyl)-phenyl-2-cyano-3-hydroxy-hept-2-en-6- in-carboxylic acidamide and 2-cyano-3-cyclopropyl-3-oxo-(4-cyanophenyl)propionamide or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

FIGURE 1

A)



B)




FIGURE 2




FIGURE 3

Rearing height and duration in imidazotriazinone treated animals




FIGURE 4

Locomotor recovery after spinal cord contusion and oral treatment with imidazotriazinone





FIGURE 5

BBB score at DPO 56



INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2012/054258

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/519 A61K31/53
ADD. A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LOMBARDI GIUSEPPE ET AL: "Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients.", THE JOURNAL OF SEXUAL MEDICINE MAY 2009 LNKD- PUBMED:19210710, vol. 6, no. 5, May 2009 (2009-05), pages 1248-1258, XP002674088, ISSN: 1743-6109 page 1252 - page 1256	1,5,6,8, 9,11,12
X	US 2004/097498 A1 (NIEWOHNER ULRICH [DE] ET AL NIEWOEHNER ULRICH [DE] ET AL) 20 May 2004 (2004-05-20) column 1037; example 99 column 1053; example 103 claims 1,11,18 ----- -/-	1,2,5-9, 11-13

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 April 2012

Date of mailing of the international search report

27/04/2012

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Werner, Doris

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2012/054258

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	F. GIULIANO, E. RUBIO-AURIOLES, M. KENNELLY, ET AL.: "Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury", NEUROLOGY, vol. 66, 2006, pages 210-216, XP002674089, page 210 - page 216 -----	1,5,6,8, 9,11,12
X	SCHORLEMMER H U ET AL: "Therapeutic activity of malononitrilamides (MNA 279 and MNA 715) on acute and chronic, relapsing, experimental, allergic encephalomyelitis (EAE)", DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, BIOSCIENCE EDIPRINT INC, CH, vol. 23, no. 5-6, 1 January 1997 (1997-01-01), pages 175-181, XP009153516, ISSN: 0378-6501 the whole document -----	14,15
A	GB 2 388 111 A (BAYER AG [DE]) 5 November 2003 (2003-11-05) claims and examples -----	1-15
A	WO 02/098879 A1 (BAYER AG [DE]; ALONSO-ALIJA CRISTINA [DE]; GIELEN HEIKE [DE]; HENDRIX) 12 December 2002 (2002-12-12) examples 7,8 -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2012/054258

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2004097498	A1	20-05-2004	AT 288916 T 15-02-2005
		AU 4063701 A 12-09-2001	
		AU 2001240637 B2 09-03-2006	
		BR 0108853 A 29-04-2003	
		CA 2401834 A1 07-09-2001	
		CN 1407986 A 02-04-2003	
		DE 10010067 A1 06-09-2001	
		DE 50105308 D1 17-03-2005	
		DK 1280805 T3 11-04-2005	
		EP 1280805 A1 05-02-2003	
		ES 2236190 T3 16-07-2005	
		HK 1055423 A1 25-08-2006	
		JP 2003525293 A 26-08-2003	
		MX PA02008505 A 28-01-2003	
		PL 366058 A1 24-01-2005	
		PT 1280805 E 30-06-2005	
		US 2004097498 A1 20-05-2004	
		US 2005267112 A1 01-12-2005	
		WO 0164677 A1 07-09-2001	
		ZA 200206217 A 05-08-2003	
GB 2388111	A	05-11-2003	AU 2003224113 A1 17-11-2003
			CA 2484983 A1 13-11-2003
			EP 1504006 A1 09-02-2005
			GB 2388111 A 05-11-2003
			JP 2005531550 A 20-10-2005
			US 2005272732 A1 08-12-2005
			WO 03093270 A1 13-11-2003
WO 02098879	A1	12-12-2002	BG 108381 A 30-11-2004
			BR 0210910 A 08-06-2004
			CA 2449095 A1 12-12-2002
			CN 1512993 A 14-07-2004
			CO 5540381 A2 29-07-2005
			CZ 20033275 A3 17-03-2004
			EC SP034872 A 28-01-2004
			EE 200300570 A 15-04-2004
			EP 1399447 A1 24-03-2004
			HR 20031090 A2 31-08-2005
			HU 0400773 A2 28-07-2004
			JP 2004536078 A 02-12-2004
			MX PA03010985 A 28-10-2004
			NO 20035324 A 28-11-2003
			NZ 529848 A 24-02-2006
			PE 02312003 A1 16-05-2003
			PL 366906 A1 07-02-2005
			SK 14672003 A3 03-08-2004
			SV 2003001061 A 18-03-2003
			UA 75149 C2 16-02-2004
			US 2003139415 A1 24-07-2003
			US 2005065153 A1 24-03-2005
			UY 27312 A1 28-02-2003
			WO 02098879 A1 12-12-2002
			ZA 200309111 A 24-11-2004